FDA calendar · August 2021 · built from SEC filings

PDUFA dates August 2021: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in August 2021. The FDA calendar also recorded 13 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in August 2021

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

August 2021: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
August 6, 2021Nexviazyme (avalglucosidase alfa-ngpt)SNYFDA approval—ApprovedopenFDA Drugs@FDA
August 10, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 12, 2021Xywav (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate)JAZZLabel expansion—ApprovedopenFDA Drugs@FDA
August 13, 2021Lyumjev (insulin lispro-aabc)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
August 13, 2021WELIREG® (belzutifan)MRKFDA approval—ApprovedopenFDA Drugs@FDA
August 17, 2021Jemperli (dostarlimab-gxly)GSKFDA approval—ApprovedopenFDA Drugs@FDA
August 19, 2021Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
August 23, 2021Xarelto (rivaroxaban)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
August 30, 2021Invega Hafyera (paliperidone palmitate)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
August 31, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
August 31, 2021BRUKINSA® (zanubrutinib)ONCLabel expansion—ApprovedopenFDA Drugs@FDA

August 2021: dated readouts

DateDrugCompanyEventIndicationStatusSource
Aug 2021Month disclosedMVASI® (bevacizumab)OTLKTopline readout—Met primary endpointSEC Form 10-K
Aug 2021Month disclosedLucentis® (ranibizumab)OTLKTopline readout—Met primary endpointSEC Form 10-K

Questions

What PDUFA dates are in August 2021?

0 PDUFA dates fell in August 2021. The FDA calendar also recorded 13 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.